PMID- 11022676
OWN - NLM
STAT- MEDLINE
DCOM- 20001124
LR  - 20110726
IS  - 0301-4894 (Print)
IS  - 0301-4894 (Linking)
VI  - 101
IP  - 9
DP  - 2000 Sep
TI  - [Human tumor-rejection antigens and peptides from genes to clinical research].
PG  - 612-7
AB  - One of the most significant advances in the field of modern tumor immunology is 
      the identification of genes encoding tumor-rejection antigens that are recognized 
      by human leukocyte antigen (HLA) class I-restricted and tumor-specific cytotoxic 
      T lymphocytes (CTLs). Several peptides encoded by these genes are now under 
      clinical trial as cancer vaccines, and major tumor regression has been observed 
      in some melanoma patients. These results indicate that identification of the 
      peptides capable of inducing CTLs may provide a new modality of cancer therapy. 
      We investigated tumor-rejection antigens from epithelial cancers, and reported 7 
      genes encoding tumor-rejection antigens and peptides available for specific 
      immunotherapy of HLA-A26 or -A24 patients with epithelial cancers. Furthermore, 
      we identified more than 10 genes encoding tumor-rejection antigens and peptides 
      available for specific immunotherapy of HLA-A2 patients with epithelial cancers. 
      Therefore these new antigens and peptides could be applicable to the treatment of 
      numerous epithelial cancer patients worldwide. Phase I clinical trials of cancer 
      vaccine with these peptides for epithelial cancer patients are in progress at our 
      university. Basic and clinical research will provide new insights for a better 
      understanding of the molecular basis of T cell-mediated recognition of cancer 
      cells and be important for the development of cancer vaccines.
FAU - Itoh, K
AU  - Itoh K
AD  - Department of Immunology, Kurume University School of Medicine, Japan.
FAU - Yamana, H
AU  - Yamana H
FAU - Shichijo, S
AU  - Shichijo S
FAU - Yamada, A
AU  - Yamada A
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Geka Gakkai Zasshi
JT  - Nihon Geka Gakkai zasshi
JID - 0405405
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigens, Neoplasm/*genetics
MH  - Cancer Vaccines/*immunology
MH  - HLA Antigens/immunology
MH  - Humans
MH  - Melanoma/immunology
MH  - Neoplasms/immunology/*therapy
MH  - Peptides/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
RF  - 18
EDAT- 2000/10/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/07 11:00
PHST- 2000/10/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/07 11:00 [entrez]
PST - ppublish
SO  - Nihon Geka Gakkai Zasshi. 2000 Sep;101(9):612-7.